252 related articles for article (PubMed ID: 20419092)
1. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Hu J; Ljubimova JY; Inoue S; Konda B; Patil R; Ding H; Espinoza A; Wawrowsky KA; Patil C; Ljubimov AV; Black KL
PLoS One; 2010 Apr; 5(4):e10108. PubMed ID: 20419092
[TBL] [Abstract][Full Text] [Related]
2. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model.
Black KL; Yin D; Ong JM; Hu J; Konda BM; Wang X; Ko MK; Bayan JA; Sacapano MR; Espinoza A; Irvin DK; Shu Y
Brain Res; 2008 Sep; 1230():290-302. PubMed ID: 18674521
[TBL] [Abstract][Full Text] [Related]
3. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
[TBL] [Abstract][Full Text] [Related]
4. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
[TBL] [Abstract][Full Text] [Related]
5. Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor.
Sommer F
Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):295-301. PubMed ID: 16922644
[TBL] [Abstract][Full Text] [Related]
6. Vardenafil: efficacy, tolerability and future directions.
Rice KR; Dean RC
Expert Opin Drug Metab Toxicol; 2009 May; 5(5):553-62. PubMed ID: 19416089
[TBL] [Abstract][Full Text] [Related]
7. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
8. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction.
van der Made F; Bloemers J; Yassem WE; Kleiverda G; Everaerd W; van Ham D; Olivier B; Koppeschaar H; Tuiten A
J Sex Med; 2009 Mar; 6(3):777-90. PubMed ID: 19207276
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Prisant LM
Curr Hypertens Rep; 2006 Aug; 8(4):345-51. PubMed ID: 16884667
[TBL] [Abstract][Full Text] [Related]
10. A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway.
Sahara M; Sata M; Morita T; Nakajima T; Hirata Y; Nagai R
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1315-24. PubMed ID: 20413734
[TBL] [Abstract][Full Text] [Related]
11. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
[TBL] [Abstract][Full Text] [Related]
13. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
Chen JJ; Sun YL; Tiwari AK; Xiao ZJ; Sodani K; Yang DH; Vispute SG; Jiang WQ; Chen SD; Chen ZS
Cancer Sci; 2012 Aug; 103(8):1531-7. PubMed ID: 22578167
[TBL] [Abstract][Full Text] [Related]
14. PDE5 inhibition against acute renal ischemia reperfusion injury in rats: does vardenafil offer protection?
Kyriazis I; Kagadis GC; Kallidonis P; Georgiopoulos I; Marazioti A; Geronasiou A; Liourdi D; Loudos G; Schinas V; Apostolopoulos D; Papadaki H; Flordellis C; Nikiforidis GC; Papapetropoulos A; Liatsikos EN
World J Urol; 2013 Jun; 31(3):597-602. PubMed ID: 23143734
[TBL] [Abstract][Full Text] [Related]
15. Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats.
Matsumoto S; Hanai T; Uemura H
Int Urol Nephrol; 2010 Mar; 42(1):53-6. PubMed ID: 19449122
[TBL] [Abstract][Full Text] [Related]
16. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
[TBL] [Abstract][Full Text] [Related]
17. Is vardenafil "noninferior" or superior to sildenafil in the management of erectile dysfunction? Revisiting the biochemical, physiological, and clinical evidence.
Traish A; Kim N
J Sex Med; 2008 Jul; 5(7):1762-8; discussion 1768-9. PubMed ID: 18221281
[No Abstract] [Full Text] [Related]
18. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?
Chivers ML; Rosen RC
J Sex Med; 2010 Feb; 7(2 Pt 2):858-72. PubMed ID: 19929916
[TBL] [Abstract][Full Text] [Related]
19. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
[TBL] [Abstract][Full Text] [Related]
20. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
